Navigation Links
University of Vermont Health Network Ventures and Wilson Sonsini Goodrich & Rosati Invest in Biofactura, Inc.
Date:6/1/2019

The University of Vermont Health Network Ventures and legal firm Wilson Sonsini Goodrich & Rosati recently invested in BioFactura’s $6M Series B Financing Round.

“With the commitment from the UVM fund and WSGR, BioFactura is now securing value-added institutional investors who bring significant financial and business resources to bear as we advance our biopharmaceutical products to the clinic,” said Darryl Sampey, BioFactura’s President and CEO.

Dr. Jeffrey Hausfeld, Chairman of the Board and Chief Medical Officer, stated, “We are excited to work with the University of Vermont Health Network Ventures and WSGR and view them as important strategic investors in BioFactura. Both our Biosimilars and Biodefense drugs promote the health and safety of our patients using innovative, state of the art, biopharmaceutical manufacturing techniques. Improving access to highly effective biologic therapeutics, while bending the cost curve downwards in a meaningful way, are shared goals.”

Chris Jones, Director of Venture Investments for the UVM Health Network, commented, "Investments into biosimilars are directly aligned with the mission of improving access to care and reducing costs. There are additional benefits that BioFactura has revealed, such as improved quality and emergency preparedness, and I predict we will be seeing a lot of interest in this space and in this company going forward."

Charles Andres Ph.D., RAC, Associate Attorney specializing in Intellectual Property states, “WS Investments, the investment fund of Wilson, Sonsini, Goodrich & Rosati, was pleased to participate in the round.”

About BioFactura, Inc.
BioFactura, Inc. (Frederick MD) develops and commercializes high-value, highly similar biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast™ Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases. http://www.biofactura.com

About University of Vermont Health Network Ventures
University of Vermont Health Network Ventures is the highly selective, mission-led ventures arm of Vermont’s 6-hospital healthcare system. http://www.uvmhealth.org

About Wilson Sonsini Goodrich & Rosati
Wilson Sonsini Goodrich & Rosati is a law firm in the United States that specializes in business, securities, and intellectual property law. WSGR provides legal services to technology, life sciences, and growth enterprises worldwide, as well as the venture capital firms, private equity firms, and investment banks that finance them. The firm's clients operate in a range of technology industries, including the biotech, communications, digital media, energy, financial services, medical devices, mobile, semiconductor, and software sectors. http://www.wsgr.com

Read the full story at https://www.prweb.com/releases/university_of_vermont_health_network_ventures_and_wilson_sonsini_goodrich_rosati_invest_in_biofactura_inc/prweb16288101.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. uBiome Awards Grant to Stanford University to Study the Effect of Semen Microbiome on Fertilization and Embryo Development
2. Sensors Midwest Partners with Fraunhofer USA and Sonoma State University, CA, to host IoT Enabled Industry 4.0 Certification Workshop
3. Stephen Zarrilli Named President & CEO of University City Science Center
4. IBM Research and Cornell University to Use Genetic Sequencing and Big Data Analytics to Help Keep Global Milk Supply Safe
5. Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas
6. Temple University School of Medicine receives Grand Challenges Explorations grant
7. BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree
8. University of Delaware study connects penguin chick weights to local weather conditions
9. Johannes Gutenberg University Mainz joins Germanys Gauss-Allianz as a full member
10. The Genome Institute at Washington University Receives Irys System from BioNano Genomics to Advance Research for Genome Reference Consortium
11. University of Washington biotech start-up to develop game-changing cancer therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2020)... ... July 17, 2020 , ... Commercial launch readiness is a ... to discover a COVID cure or vaccine, the global economic downturn will only increase ... is not going away and capturing full value from every product launch is critical. ...
(Date:7/4/2020)... , ... July 03, 2020 , ... ... to earn outstanding recognition and multiple awards for not only the products and ... portfolio, SoME® Skincare and Vivace® Microneedle RF. All the brands built by ABM ...
(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, a global leader in ... Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan. , ... Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical supply solutions, ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... (PRWEB) , ... August 12, 2020 , ... ... Inc. (EMMA International), a global leader in FDA compliance consulting has been ... nation’s fastest-growing private companies. The list represents a unique look at the most ...
(Date:7/31/2020)... ... 29, 2020 , ... R3 Stem Cell International is now offering patients the ... stem cells total, patients may choose which extremities they would like treated. , Several ... Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab ...
(Date:7/31/2020)... ... July 29, 2020 , ... Editas Medicine, ... provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell ... into a strategic partnership whereby Catalent will provide support for the development, manufacturing, ...
(Date:7/22/2020)... ... 22, 2020 , ... Join experts from Reed Tech , Gary Saner, ... a one hour live webinar on Thursday, August 13, 2020 at 11am ... and medical devices. Specifically, for medical devices, the NMPA has departments dealing with medical ...
Breaking Biology Technology: